# PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers

> **NCT05723510** · PHASE1 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 87 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tegoprazan 50mg
- **DRUG:** Edoxaban 60mg
- **DRUG:** Apixaban 5mg
- **DRUG:** Rivaroxaban 20mg

## Key facts

- **NCT ID:** NCT05723510
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-06
- **Primary completion:** 2023-07-17
- **Final completion:** 2023-07-24
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05723510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05723510, "PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05723510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*